CH Basel Uteng M: Difference between revisions
From Bioblast
No edit summary |
No edit summary |
||
Line 7: | Line 7: | ||
|Team previous=Dong Min | |Team previous=Dong Min | ||
|Status=O2k 2006- | |Status=O2k 2006- | ||
|info=[ | |info=[[MiPNet12.14 IOC39|IOC39]], [[MiPNet11.06 IOC36|IOC36]] | ||
}} | }} | ||
* Previously CH_Muttenz_Dong M | * Previously CH_Muttenz_Dong M |
Revision as of 08:55, 14 June 2016
CH Basel Uteng M
O2k-Network Lab | Novartis Pharma AG, Werk Klybeck |
---|---|
Address | , 4002 |
City | Basel |
State/Prov | |
Country | Switzerland |
Weblink | |
Contact | |
Team | Riebel Virginie |
Team previous | Dong Min |
Status | O2k 2006- |
Oroboros Events | IOC39, IOC36 |
Topics |
O2k-Publications
Published | Reference | |
---|---|---|
Brecht 2016 Toxicol In Vitro | 2016 | Brecht K, Riebel V, Couttet P, Paech F, Wolf A, Chibout SD, Pognan F, KrΓ€henbΓΌhl S, Uteng M (2016) Mechanistic insights into selective killing of OXPHOS-dependent cancer cells by arctigenin. Toxicol In Vitro 40:55-65. |
O2k-Abstracts
update please
- Previously CH_Muttenz_Dong M